Skip to content
Clinical Trials – home
GreeceBack to Greece

Clinical trials in Nea Ionia – page 10

1 034 clinical trials in Nea Ionia, Greece across 1 research site. Every trial is listed in the EU Clinical Trials Register and updated daily.

GreeceOur site in GreeceΚλινικεσΔοκιμεσ.gr(opens in a new tab)
Nea Ionia at a glance
1 034
clinical trials
  • Research sites1
Type of trial
Recruitment status
Quick filters

1 034 trials in Nea Ionia

Open in trial search

Phase 3 Study of Enpatoran in Patients with Active Cutaneous Lupus Erythematosus (with or without Systemic Disease)

Investigational
Countries:GreeceGreece
  • Participants:18–64 years · 65+ years
  • Substances:Enpatoran hemihydrate
  • Sponsor:Merck Healthcare KGaA

Study of telisotuzumab adizutecan plus drug combination in adults with refractory metastatic colorectal cancer

Registered drugNo placebo
Countries:GreeceGreece
  • Participants:18–64 years · 65+ years
  • Substances:Bevacizumab
  • Sponsor:AbbVie Deutschland GmbH & Co. KG

A Phase 2a Study Evaluating the Efficacy and Safety of MK-8690 in Adults with Moderately to Severely Active Ulcerative Colitis

Investigational
Countries:GreeceGreece
  • Participants:18–64 years · 65+ years
  • Substances:MK-8690
  • Sponsor:Merck Sharp & Dohme LLC

Efficacy and safety of sarilumab plus prednisone versus prednisone alone in adults with early polymyalgia rheumatica

Registered drug
Countries:GreeceGreece
  • Participants:18–64 years · 65+ years
  • Substances:Prednisone
  • Sponsor:Sanofi-Aventis Recherche & Developpement

Study of MK-1045 versus blinatumomab with tocilizumab in patients with relapsed or refractory B-cell acute lymphoblastic leukemia

Registered drugNo placebo
Countries:GreeceGreece
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Blinatumomab
  • Sponsor:Merck Sharp & Dohme LLC

Study of MK-1084 plus durvalumab versus placebo plus durvalumab in patients with locally advanced KRAS G12C‑mutant non‑small cell lung cancer after chemoradiotherapy

Registered drug
Countries:GreeceGreece
  • Participants:18–64 years · 65+ years
  • Substances:Durvalumab
  • Sponsor:Merck Sharp & Dohme LLC

Rifabutin plus drug combination for adult patients with hospital‑acquired and ventilator‑associated pneumonia caused by carbapenem‑resistant Acinetobacter baumannii

Registered drugNo placebo
Countries:GreeceGreece
  • Participants:18–64 years · 65+ years
  • Substances:Ampicillin Sodium
  • Sponsor:Bioversys S.A.S.

Study of MK-1045 plus rituximab in patients with newly diagnosed follicular lymphoma

Registered drugNo placebo
Countries:GreeceGreece
  • Participants:18–64 years · 65+ years
  • Substances:Cyclophosphamide
  • Sponsor:Merck Sharp & Dohme LLC

Study of MK-6070 drug combination in first-line extensive-stage small cell lung cancer patients

Registered drugNo placebo
Countries:GreeceGreece
  • Participants:18–64 years
  • Substances:Atezolizumab
  • Sponsor:Merck Sharp & Dohme LLC

Metronidazole, Bismuth Oxide and Tetracycline Hydrochloride Fixed‑Dose Combination vs Standard First‑line Therapy for Adults with Helicobacter pylori Infection

Registered drugNo placebo
Countries:GreeceGreece
  • Participants:18–64 years · 65+ years
  • Substances:Amoxicillin
  • Sponsor:Verisfield Single Member S.A.

Pumitamig Versus Durvalumab in Patients With Unresectable Stage III Non-Small Cell Lung Cancer Without Progression After Chemoradiation

Registered drugNo placebo
Countries:GreeceGreece
  • Participants:18–64 years · 65+ years
  • Substances:Durvalumab
  • Sponsor:Bristol-Myers Squibb Services Unlimited Company

EIK1001, Pembrolizumab, and Chemotherapy for Stage 4 Non-Small Cell Lung Cancer in Patients with Stage 4 Non-Small Cell Lung Cancer

Registered drug
Countries:GreeceGreece
  • Participants:18–64 years · 65+ years
  • Substances:Pembrolizumab
  • Sponsor:Eikon Therapeutics Inc.

Other cities in Greece

The busiest research cities in the country

All 47 cities in Greece

Clinical research in Nea Ionia

What the registry says about research in the country

01 Cardiovascular Disease Management

Innovative research focusing on lipoprotein reduction and prevention of major cardiovascular events in patients with established CVD. Studies evaluate new therapeutic approaches for reducing cardiovascular risks.

  • Cardiovascular event prevention
  • Lipoprotein management
  • Heart disease treatments

Advanced trials exploring novel compounds for improved patient outcomes.

02 Atrial Fibrillation Treatment

Comprehensive studies examining various approaches to manage atrial fibrillation, including new medications for stroke prevention and cardiac rhythm control.

  • Stroke prevention therapies
  • Cardioversion treatments
  • Anticoagulation management

Multiple therapeutic options being evaluated for different patient populations.

03 Heart Failure Research

Investigation of innovative treatments for chronic heart failure, focusing on patients with reduced ejection fraction and those with kidney complications.

  • Medication effectiveness studies
  • Combined therapy approaches
  • Cardiovascular outcomes

Evaluating new therapeutic combinations to improve patient survival and quality of life.

Clinical Trials Concierge

Prefer not to search on your own, or looking for clinical trials for a rare disease?

Tell us about your condition – we search every trial in Europe and connect you with the right site.